It is currently difficult to determine which drug might work for each epilepsy patient. Therefore, the biopharmaceutical company UCB has been collaborating with Georgia Tech to explore predictors of medication success to help identify the best treatment option for an epilepsy patient faster. The technology uses machine learning techniques based on large quantities of health data. Demonstrations on the interoperability of the technology have been conducted using patient data provided by the U.S. Department of Veterans Affairs via a public-private partnership.
In fiscal year 2018, the project team began the quality assurance and validation process for the predictive model and its algorithms.